Integrated computational screen and validation of thalidomide-based PROTACs targeting SARS-CoV-2 main protease

RSC Medicinal Chemistry 2026 Open access

Read full text
Authors: Li-Na Guo, Yu-Hua Li, Rou-Yu Zhu, Ni Su, Zhiyu Shao, Hua Jia Diao
DOI: 10.1039/d5md01003a
Cited by: 1
References: 37

Abstract

Three novel thalidomide-based PROTACs (A, B, and C) demonstrate efficient binding to and degradation of SARS-CoV-2 M pro in transfected HEK293 cells with high selectivity, mediated through the ubiquitin–proteasome system.

Fields of Study & Subjects

Protein Degradation and Inhibitors Chromatin Remodeling and Cancer PARP inhibition in cancer therapy

Publication details

Journal / source
RSC Medicinal Chemistry
Publisher
Royal Society of Chemistry (RSC)
Volume
17
Issue
2
Pages
1135–1143
Publication date
1 January 2026
Language
EN